SILO PHARMA INC. - COMMON STOCK

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

26 Mar 2025 08:40:00 By Nasdaq GlobeNewswire

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

26 Feb 2025 13:30:00 By Nasdaq GlobeNewswire

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

18 Feb 2025 08:50:00 By Nasdaq GlobeNewswire

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

11 Feb 2025 07:45:00 By Nasdaq GlobeNewswire

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

22 Jan 2025 08:29:00 By Nasdaq GlobeNewswire

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

08 Jan 2025 08:29:00 By Nasdaq GlobeNewswire

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

02 Jan 2025 08:45:00 By Nasdaq GlobeNewswire

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

18 Dec 2024 07:35:00 By Nasdaq GlobeNewswire

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

29 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

18 Nov 2024 08:40:00 By Nasdaq GlobeNewswire

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

31 Oct 2024 08:35:00 By Nasdaq GlobeNewswire

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

10 Sep 2024 06:35:00 By Nasdaq GlobeNewswire

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

14 Aug 2024 14:30:00 By Nasdaq GlobeNewswire

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

07 Aug 2024 08:13:00 By Nasdaq GlobeNewswire

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

26 Jul 2024 08:20:00 By Nasdaq GlobeNewswire

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

22 Jul 2024 16:45:00 By Nasdaq GlobeNewswire

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

19 Jul 2024 08:01:00 By Nasdaq GlobeNewswire

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

18 Jul 2024 08:25:00 By Nasdaq GlobeNewswire

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

16 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

30 Mar 2022 08:30:00 By Nasdaq GlobeNewswire